APTIVUS

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Croatia, Estonia, France, Ireland, Lithuania, Poland, South Africa, Spain, UK.

Active ingredients

The drug APTIVUS contains one active pharmaceutical ingredient (API):

1	Tipranavir UNII ZZT404XD09 - TIPRANAVIR
	Tipranavir is a non-peptidic inhibitor of the HIV-1 protease that inhibits viral replication by preventing the maturation of viral particles.
	Read more about Tipranavir

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
APTIVUS Soft capsules	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AE09	Tipranavir	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AE Protease inhibitors
Discover more medicines within J05AE09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10344K
CA	Health Products and Food Branch	02273322
EE	Ravimiamet	1218833, 1423820
ES	Centro de información online de medicamentos de la AEMPS	05315001
FR	Base de données publique des médicaments	67219072, 68530375
GB	Medicines & Healthcare Products Regulatory Agency	97472
LT	Valstybinė vaistų kontrolės tarnyba	1027444, 1050605
PL	Rejestru Produktów Leczniczych	100074662, 100308597
US	FDA, National Drug Code	0597-0002, 0597-0003
ZA	Health Products Regulatory Authority	43/20.2.8/0226